Core Scientific, Inc./tx Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $81.1M | — | -$146.7M | — | -$57.4M | -$0.46 |
| Q2 FY202510-Q · 2025-06-30 | $62.4M | — | -$936.8M | — | -$26.3M | -$0.04 |
| Q1 FY202510-Q · 2025-03-31 | $67.2M | — | $580.7M | — | -$42.6M | $1.25 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $2.3B | $3.4B | $453.4M | -$1.1B |
| Q2 FY202510-Q | $2.0B | $3.0B | $581.3M | -$1.1B |
| Q1 FY202510-Q | $1.6B | $1.8B | $697.9M | $3.0B |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | -$57.4M | -$146.7M | $3.9M | 308,381,000 |
| Q2 FY202510-Q | -$26.3M | -$936.8M | $1.1M | 303,146,000 |
| Q1 FY202510-Q | -$42.6M | $580.7M | $467.0K | 299,087,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from Core Scientific, Inc./tx's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].